Korean J Gastroenterol.  2013 Aug;62(2):140-141. 10.4166/kjg.2013.62.2.140.

Is Classification of Gastric Cancer According to Distinct Therapeutic Targets Applicable in Clinical Practice?

• Kim KM

• KMID: 1775754
• DOI: http://doi.org/10.4166/kjg.2013.62.2.140

Abstract

No abstract available.

MeSH Terms

*Gene Amplification
*Gene Deletion
*Polymorphism, Single Nucleotide
Stomach Neoplasms/*genetics

Reference

References

1. Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012; 61:673–684.

2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–2917.

3. Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376:687–697.

4. Cheung DY, Kim JK. Perspectives of the stomach cancer treatment: the introduction of molecular targeted therapy and the hope for cure. Korean J Gastroenterol. 2013; 61:117–127.

5. Kwei KA, Bashyam MD, Kao J, et al. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet. 2008; 4:e1000081.